{
    "nct_id": "NCT05469178",
    "official_title": "Phase 1b/2a Safety and Tolerability Study of Bemcentinib with Pembrolizumab/carboplatin/pemetrexed in Subjects with Untreated Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Without/with a STK11 Mutation",
    "inclusion_criteria": "* Histologically-confirmed or cytologically confirmed diagnosis of advanced (Stage IIIb/IIIc) or metastatic (Stage IV) (AJCC Edition 8) non-squamous NSCLC not amenable to curative therapy, irrespective of PD-L1 status and without actionable mutations (Phase 1b) targetable with first-line treatment.\n* Histologically-confirmed or cytologically confirmed diagnosis of stage of advanced (Stage IIIb/IIIC) or metastatic (Stage IV) (AJCC, Edition 8) non-squamous NSCLC with STK11 mutation, not amenable to curative therapy, irrespective of PD-L1 status and without actionable mutations (phase 2a) targetable with first-line treatment.\n* Have not received prior systemic treatment for their advanced/metastatic NSCLC\n* Have measurable disease per RECIST 1.1 as assessed by the investigator\n\nMain\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has received any prior chemotherapy or biological therapy for locally advanced (Stage IIIb/IIIc) or metastatic (Stage IV) adenocarcinoma of the lung\n* Received radiation therapy within 2 weeks prior to starting study treatment or has not recovered (i.e. <=Grade 1 at baseline) from AEs due to a previous radiation therapy\n* Major surgery within 28 days prior to start of study treatment and failure to have recovered adequately from the complications of the surgery/intervention prior to the first dose of study treatment",
    "miscellaneous_criteria": "Main"
}